HC Wainwright Issues Positive Estimate for FULC Earnings

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) – Equities research analysts at HC Wainwright raised their Q3 2025 earnings per share (EPS) estimates for Fulcrum Therapeutics in a report issued on Tuesday, July 29th. HC Wainwright analyst A. Fein now forecasts that the company will earn ($0.26) per share for the quarter, up from their previous forecast of ($0.28). HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Fulcrum Therapeutics’ current full-year earnings is ($0.16) per share. HC Wainwright also issued estimates for Fulcrum Therapeutics’ Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($1.10) EPS, FY2026 earnings at ($1.27) EPS, FY2027 earnings at ($1.26) EPS, FY2028 earnings at ($0.96) EPS and FY2029 earnings at ($0.65) EPS.

A number of other equities analysts also recently commented on FULC. Piper Sandler reissued an “overweight” rating and issued a $9.00 target price (up previously from $6.00) on shares of Fulcrum Therapeutics in a research note on Thursday, May 29th. Royal Bank Of Canada raised their price objective on Fulcrum Therapeutics from $4.00 to $5.00 and gave the company a “sector perform” rating in a research report on Wednesday. Leerink Partners raised Fulcrum Therapeutics from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $4.00 to $12.00 in a research report on Friday, May 23rd. Cantor Fitzgerald upgraded Fulcrum Therapeutics from a “neutral” rating to an “overweight” rating and set a $10.00 target price for the company in a research note on Thursday, May 15th. Finally, Leerink Partnrs raised Fulcrum Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Friday, May 23rd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $7.57.

Fulcrum Therapeutics Stock Up 1.5%

Shares of FULC stock opened at $6.83 on Friday. Fulcrum Therapeutics has a fifty-two week low of $2.32 and a fifty-two week high of $10.13. The firm’s 50 day moving average price is $7.17 and its two-hundred day moving average price is $4.99. The stock has a market cap of $369.43 million, a price-to-earnings ratio of -5.60 and a beta of 2.47.

Fulcrum Therapeutics (NASDAQ:FULC) last issued its earnings results on Tuesday, July 29th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.01.

Institutional Trading of Fulcrum Therapeutics

Several large investors have recently modified their holdings of the business. American Century Companies Inc. boosted its holdings in Fulcrum Therapeutics by 5.9% in the fourth quarter. American Century Companies Inc. now owns 120,611 shares of the company’s stock valued at $567,000 after purchasing an additional 6,770 shares during the last quarter. Wells Fargo & Company MN raised its position in shares of Fulcrum Therapeutics by 34.4% in the 4th quarter. Wells Fargo & Company MN now owns 34,264 shares of the company’s stock valued at $161,000 after purchasing an additional 8,761 shares in the last quarter. ADAR1 Capital Management LLC boosted its stake in shares of Fulcrum Therapeutics by 177.2% during the 4th quarter. ADAR1 Capital Management LLC now owns 196,248 shares of the company’s stock valued at $922,000 after buying an additional 125,446 shares during the last quarter. Mariner LLC acquired a new stake in shares of Fulcrum Therapeutics during the fourth quarter worth approximately $78,000. Finally, Zacks Investment Management acquired a new stake in shares of Fulcrum Therapeutics during the fourth quarter worth approximately $99,000. 89.83% of the stock is currently owned by institutional investors and hedge funds.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.